Isconova gets $5.2M for vaccine work

Sweden's Isconova has secured financing of 30 million Swedish kronor ($5.2 million) from InnovationsKapital for its work in vaccine adjuvant technology. Isconova release

Suggested Articles

Janssen’s BCMA-targeting CAR-T therapy eliminated tumors in 69% of patients with advanced multiple myeloma in a small phase 1 study.

In a study, BMS' CAR-T therapy banished tumors in more than half and shrank tumors in nearly three-quarters of relapsed blood cancer patients.

Novartis unveiled more data showing how its asthma combo QMF149 fared against the standard of care: a combination of the same types of drugs.